Skip to main content
GutCited

Bifidobacterium breve para Irritable Bowel Syndrome (IBS)

D

Limited data from small studies. Preliminary evidence for symptom improvement.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

Conclusión

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None vs: None Outcome: None Efecto: None None

Población: None

Other n=1098 8 weeks Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None vs: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Efecto: 73% pain, 81.9% bloating success at T1 <0.001

Población: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None vs: Placebo Outcome: IBS-SSS symptom severity score change Efecto: None None

Población: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g vs: Placebo Outcome: Constipation symptoms Efecto: None P = 0.005

Población: IBS patients

Review
Postbiotics: A new member in the biotics family.
Dose: None vs: None Outcome: Clinical applications overview Efecto: None None

Población: General population (review)

In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None vs: None Outcome: Colitis severity Efecto: None None

Población: Crohn's disease patients

Key Statistics

2

Estudios

150

Participantes

Positive

D

Calificación

Referenced Papers

Archivos argentinos de … 2024 3 citas
Journal of clinical … 2004 205 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:
1-10 billion CFU/day
adultgisupport:
5-10 billion CFU/day
neonatalsupport:
1-5 billion CFU/day (as directed by pediatrician)

Límite superior: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
None -- Mixed --
None 8 weeks Positive 1098
None 8 weeks Neutral 61
2 g 4 weeks Mixed --
None -- Positive --
None -- Positive --
Serum-derived bovine immunoglobulin (SBI) -- Positive --
None -- Positive --

Mejor momento para tomar: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Efectos secundarios reportados

  • Mild gas during initial use
  • Occasional loose stools in infants (transient)
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Interacciones conocidas

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Ingesta máxima tolerable: Well-tolerated up to 10 billion CFU/day in clinical trials

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Related Evidence

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.